Referentielijst


Introduction:


Système cardiovasculaire:


Système gastro-intestinal:


Système respiratoire:


Système hormonal:


Système uro-génital:


Douleur et fièvre:


Soins palliatifs – Soins de fin de vie:


Pathologies ostéo-articulaires:


Système nerveux:


Maladies infectieuses:


Vitamines et minéraux:

  • 1 Conseil Supérieur de la Santé. Recommandationsnutritionnelles pour la Belgique. Révision 2009. CSS n° 8309. http://www.health.belgium.be/eportal/Aboutus/relatedinstitutions/SuperiorHealthCouncil/publications/booklets/index.htm?&fodnlang=fr.
  • 2 JudgeDE. Vitamin D and calcium: what women need at midlife and after. Journal Watch Women’s Health 2013;Feb 28.
  • 3 Gezondheidsraad. Naar een toereikende innamevan vitamine D. Den Haag: Gezondheidsraad, 2008; publicatienr 2008/09.
  • 4 Conseil Supérieurde la Santé. Recommandations nutritionnelles pour la Belgique. Révision 2009. www.health.fgov.be/CSS_HGR.
  • 5 Chausmer AB. Dose response to vitaminD supplementation in postmenopausal women. (Letter) Ann InternMed 2012;157:384.
  • 6 Barake M, DaherRT, Salti I, et al. 25-hydroxyvitamin D assay variations and impacton clinical decision making. J Clin Endocrinol Metab 2012;97:835-43.
  • 7 Bedner M, Lippa KA, Tai SS.An assessment of 25-hydroxyvitamine D measurements in comparabilitystudies conducted by the vitamin D metabolites quality assurance program. Clin Chim Acta 2013;Aug 24, doi: 10.1016/j.cca.2013.08.012.
  • 8 Holick FH. Vitamin D deficiency. N EnglJ Med 2007;357:266-81.
  • 9 EPHOR. Advies VitamineD suppletie bij ouderen. Ephor 2012 http://ephor.artsennet.nl/.
  • 10 Rédaction Prescrire. “Insuffisance” envitamine D chez les adultes. Gare aux concepts trop flous pour rendreservice aux patients. Revue Prescrire 2013;33(356):435-8.
  • 11 Medical Advisory Secretariat. Clinicalutility of vitamin D testing: an evidence-based analysis. Ont HealthTechnol Assess Ser [Internet]. 2010 Feb [cited 2010 06 01]; 10(2)1-95. http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/rev_vitamind_201002.pdf.
  • 12 Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011;86(1):50-60.
  • 13 Anonymous.Prévention et traitement de l’ostéoporose post ménopausique. FoliaPharmacotherapeutica 2007;34:55-9.www.cbip.be.
  • 14 Ross AC, Taylor CL, YaktineAL, et al. Dietary reference intakes for calcium and vitamin D. The National Academies Press, Washington DC, 2010.http://www.ncbi.nlm.nih.gov/books
  • 15 Bischoff-Ferrari HA, Dawson-Hughes B, Stahelin HB et al. Fall preventionwith supplemental and active forms of vitamin D: a meta-analysis ofrandomised controlled trials. BMJ 2009;339:b3692.
  • 16 Michael YL, Whitlock EP, Lin JS, et al. Primary care-relevant interventionsto prevent falling in older adults: a systematic evidence review forthe US Preventive Services Task Force. Ann Intern Med 2010;153:815-25.
  • 17 Moyer VA, on behalfof the U.S. Preventive Services Task Force. Prevention of falls incommunity-dwelling older adults: US preventive services task forcerecommendation statement. Ann Intern Med 2012;157:197-204.
  • 18 Zhu K, Austin N, DevineA, et al. A randomized controlled trial of the effects of vitaminD on muscle strength and mobility in older women with vitamin D insufficiency. J Am Geriatr Soc 2010;58:2063-8.
  • 19 Murad MH, Elamin KB, Abu Elnour NO, etal. The effect of vitamin D on falls: a systematic review and meta-analysis. J Clin Endocrin Metab 2011;96:doi.org/10.1210/jc.2011-1193.
  • 20 Sanders KM, Stuart AL, Williamson EJ, et al. Annual High-Dose OralVitamin D and Falls and Fractures in Older Women: A Randomized ControlledTrial. JAMA 2010;303:1815-182.
  • 21 Muir SW, Montero-OdassoM. Effect of vitamin D supplementation on muscle strenght, gait andbalance in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2011;59:2291-300.
  • 22 GillespieLD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, et al. Interventionsfor preventing falls in older people living in the community. CochraneDatabase of Systematic Reviews 2012;Issue 9. Art. No.: CD007146.DOI:10.1002/14651858.CD007146.pub3).
  • 23 Cameron ID, Murray GR, GillespieLD, Robertson MC, Hill KD, Cumming RG, Kerse N. Interventions forpreventing falls in older people in nursing care facilities and hospitals. Cochrane Database of Systematic Reviews 2010, Issue 1. Art.No.:CD005465. DOI: 10.1002/14651858.CD005465.pub2.
  • 24 Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology. 2012;79(13):1397-405.
  • 25 Bertone-Johnson ER, Powers SI, SpanglerL, et al. Vitamin D supplementation and depression in the Women’sHealth Initiative Calcium and vitamin D trial. Am J Epidemiol 2012 ;176:1-13.
  • 26 Kjaergaard M, Waterloo K, Wang CE, et al.Effect of vitamin D supplement on depression scores in people withlow levels of serum 25-hydroxyvitamin D: nested case-control studyand randomised clinical trial. Br J Psychiatry 2012; august19 doi.
  • 27 Reid IR, BollandMJ. Role of vitamin D deficiency in cardiovascular disease. Heart2012; Feb 28 doi Rejnmark L, Avenell A, Masud T, et al. Vitamin Dwith calcium reduces mortality: patient level pooled analysis of 70.528patients from eight major vitamin D trials. J Clin Endocrinol Metab 2012;97(8):doi.
  • 28 Tomson J, Emberson J, Hill M, et al. VitaminD and risk of death from vascular and non-vascular causes in the Whitehallstudy and meta-analyses of 12 000 deaths. Eur Heart J 2013;34:1365-74.
  • 29 McGreevy C,Williams D. New insights about vitamin D cardiovascular disease. Anarrative review. Ann Intern Med 2011;155:820-6.
  • 30 Elamin MB, Abu Elnour NO, Elamin KB, etal. Vitamin D and cardiovascular outcomes: a systematic review andmeta-analysis. J Clin Endocrinol 2011;96:1931-42.
  • 31 Gepner AD, RamamurthyR, Krueger DC, et al. A prospective randomized controlled trial ofthe effects of vitamin D supplementation on cardiovascular diseaserisk. Plos One 2012;7(5):e36617.
  • 32 Wood AD, Secombes KR, Thies F, et al. Vitamin D3 supplementationhas no effect on conventional cardiovascular risk factors. A parallel-group,double-blind, placebo-controlled RCT. J Clin Endocrinol Metab 2012;97:3557.
  • 33 Wang L, Manson JE, Sesso HD. Calcium intakeand risk of cardiovascular disease: a review of prospective studiesand randomized clinical trials. Am J Cardiovasc Drugs 2012;12(2):105-16.
  • 34 Al Mheid I, Patel R, Tangpricha V, et al.Vitamin D and cardiovascular disease: is the evidence solid ? EurHeart J2013 June 9;doi:10.1093/eurheartj/eht166.
  • 35 Chung M, LeeJ, Terasawa T, et al. Vitamin D with or without calcium supplementationfor prevention of cancer and fractures: an updated meta-analysis forthe U.S. preventive services task force Ann Intern Med 2011;155:827-38.
  • 36 Bjelakovic G,Gluud LL, Nikolova D, et al. Vitamin D supplementation for preventionof mortality in adults. Cochrane Database Syst Rev 2011 ;(7):CD007470.
  • 37 Rejnmark L, Avenell A, Masud T, et al.Vitamin D with calcium reduces mortality: patient level pooled analysisof 70.528 patients from eight major vitamin D trials. J Clin EndocrinolMetab 2012;97(8):doi.
  • 38 McAlindon T, LaValley M, Schneider E, etal. Effect of vitamin D supplementation on progression of knee painand cartilage volume loss in patients with symptomatic osteoarthritis.A randomized controlled trial. JAMA 2013;309:155-62.
  • 39 Grey A, Bolland M. Vitamin D supplementation and fracture risk. Arch Intern Med 2011;171:265-6.
  • 40 Bischoff-Ferrari HA,Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose reqrementsfor fracture prevention. N Engl J Med 2012;367:40-9.
  • 41 TripkovicL, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitaminD3 supplementation in raising serum 25-hydroxyvitamin D status: asystematic review and meta-analysis. Am J Clin Nutr 2012;95:1357-64.
  • 42 Farmacotherapeutisch Kompas http://www.fk.cvz.nl/
  • 43 Martindale: thecomplete drug reference. 36th edition. The Pharmaceutical Press. 2009
  • 44 de JongheHJM, Gans ROB et Huls G. Calciumsuppletie bij patiënten met maagzuurremmers.Calciumcitraat of calciumcarbonaat? Ned Tijdschr Geneeskd 2012;156:A4343.
  • 45 TaylorEN, Curhan GC. Dietary calcium from dairy and non-dairy sources andrisk of symptomatic kidney stones. J Urology 2013 26 march:doi 10.1016/j.juro2013.03.074.
  • 46 Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplementson risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
  • 47 Singh S, Furberg CD. Systematicreview: Calcium supplements increase risk of myocardial infarction. EBM 2010;15:181.
  • 48 Bolland MJ,Grey A, Avenell A, et al. Calcium supplements with or without vitaminD and risk of cardiovascular events: reanalysis of the Women’s HealthInitiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.
  • 49 Lewis JR, Calver J, Zhu K, et al. Calciumsupplementation and the risks of atherosclerotic vascular diseasein older women: results of a 5-year RCT and a 4.5 year follow-up. J Bone Miner Res 2011;26:35-41.
  • 50 Xiao Q,Murphy RA, Houston DK, et al. Dietary and supplemental calcium intakeand cardiovascular disease mortality. The National Institutes of Health-AARPdiet and health study. JAMA Intern Med 2013 ;feb4 doi.
  • 51 Michaëlsson K, Melhus H, Warensjö E, et al. Long term calcium intakeand rates of all cause and cardiovascular mortality: community basedprospective longitudinal cohort study. BMJ 2013 Feb 13;346:f228.
  • 52 Langsetmo L, Berger C, Kreiger N, et al;for the CaMos Group. Calcium and vitamin D intake and mortality :results from the Canadian multicentre osteoporosis study. J ClinEndocrin Metab 2013;98:doi.
  • 53 Li K, Kaaks R, Linseisen J, et al. Associations of dietary calciumintake and calcium supplementation with myocardial infarction andstroke risk and overall cardiovascular mortality in the Heidelbergcohort of the European prospective Investigation into Cancer and nutritionstudy (EPIC-Heidelberg). Heart 2012;98:920-5.
  • 54 EldersPJM, Dinant GJ, Van Geel T, et al. NHG-Standaard Fractuurpreventie(tweede herziening). Huisarts Wet 2012;55:4562-8.
  • 55 Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium incombination with vitamin D supplementation to prevent fractures andbone loss in people aged 50 years and older: a meta-analysis. Lancet2007; 370:657-66.
  • 56 AvenellA, Gillespie WJ, Gillespie LD, O’Connell D. Vitamin D and vitaminD-analogues for preventing fractures associated with involutionaland post-menopausal osteoporosis. Cochrane Database of SystematicReviews 2009, Issue 2. Art. No.: CD000227.DOI: 10.1002/14651858.CD000227.pub3.
  • 57 The DIPART (vitamin D Individual PatientAnalysis of Randomized Trials) Group. Patient level pooled analysisof 68.500 patients from seven major vitamin D fracture trials in USand Europe. BMJ 2010;340:b5463.
  • 58 Bolland M, Grey A, Reid I. Calciumand cardiovascular risks. Australian Prescriber 2013 ;36 :5-8.
  • 59 CommissieFarmaceutische Hulp van het College voor zorgverzekeringen. “Vitaminesen mineralen”.Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 60 Centre Belge d’Information Pharmacothérapeutique.Répertoire Commenté des Médicaments 2011. http://www.cbip.be.
  • 61 Evans JR, Lawrenson JG. Antioxidantvitamin and mineral supplements for slowing the progression of age-relatedmacular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No. CD000254. DOI: 10.1002/14651858.CD000254.pub3.
  • 62 Vivekananthan DP, Penn MS, Sapp SK et al. Useof antioxidant vitamins for the prevention of cardiovascular disease:meta-analysis of randomised trials. Lancet 2003;361:2017-23.
  • 63 Cook NR, Albert CM, Gaziano JM. Arandomized factorial trial of vitamins C and E and Beta Carotene inthe secondary prevention of cardiovascular events in women: resultsfrom the women’s antioxidant cardiovascular study. Arch InternMed 2007;167:1610-8.
  • 64 HercbergS, Galan P, Preziosi P et al. The SU.VI.MAX Study: a randomized, placebo-controlledtrial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004;164:2335-42.
  • 65 Hennekens CH, BuringJE, Manson JE et al. Lack of effect of long-term supplementation withbeta carotene on the incidence of malignant neoplasms and cardiovasculardisease. N Engl J Med 1996; 334:1145-9.
  • 66 Lee IM, Cook NR, Manson JE et al. Beta-carotenesupplementation and incidence of cancer and cardiovascular disease:the Women s Health Study. J Natl Cancer Inst 1999; 91:2102-6.
  • 67 Lin J, Cook NR, Albert C et al. VitaminsC and E and beta carotene supplementation and cancer risk: a randomizedcontrolled trial. J Natl Cancer Inst 2009; 101:14-23.
  • 68 Bjelakovic G, Nikolova D, Simonetti RGet al. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.:CD004183. DOI: 10.1002/14651858.CD004183.pub3.
  • 69 ATBC (The Alpha-Tocopherol, Beta Carotene Cancer Prevention StudyGroup). The effect of vitamin E and beta-carotene on the incidenceof lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-35.
  • 70 Omenn GS,Goodman GE, Thornquist MD et al. Effects of combination of beta caroteneand vitamin A on lung cancer and cardiovascular disease. N EnglJ Med 1996; 334:1150-5.
  • 71 BjelakovicG, Nikolova D, Gluud LL et al. Antioxidant supplements for preventionof mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.:CD007176. DOI: 10.1002/14651858.CD007176.pub2.
  • 72 Penniston KL, TanumihardjoSA. The acute and chronic toxic effects of vitamin A. Am J ClinNutr 2006; 83(2):191-201.
  • 73 Martindale: the complete drug reference. 36th edition. 2009 The PharmaceuticalPress.
  • 74 Lee IM, Cook NR, Gaziano JM et al. Vitamin E inthe primary prevention of cardiovascular disease and cancer: the Women’sHealth Study. JAMA 2005;294:56-65.
  • 75 Sesso HD, Buring JE, Christen WG et al. VitaminsE and C in the prevention of cardiovascular disease in men: the Physicians’Health Study II randomized controlled trial. JAMA 2008;300:2123-33.
  • 76 Lonn E, Bosch J, Yusuf S et al. Effectsof long-term vitamin E supplementation on cardiovascular events andcancer. JAMA 2005;293:1338-47.
  • 77 Lippman SM, Klein EA, Goodman PJ et al.Effect of selenium and vitamin E on risk of prostate cancer and othercancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
  • 78 Gaziano JM, Glynn RJ, Christen WG et al. Vitamins E and C in theprevention of prostate and total cancer in men: the Physicians HealthStudy II randomized controlled trial. JAMA 2009;301:52-62.
  • 79 Sano M, Ernesto C, ThomasRG et al. A controlled trial of selegiline, alpha-tocopherol, or bothas treatment for Alzheimer s disease. The Alzheimer s Disease CooperativeStudy. N Engl J Med 1997;336:1216-22.
  • 80 Yaffe K, Clemons TE, McBee WL et al. Impactof antioxidants, zinc, and copper on cognition in the elderly: a randomized,controlled trial. Neurology 2004;63:1705-7.
  • 81 Kang JH, Cook N, Manson J et al. A randomizedtrial of vitamin E supplementation and cognitive function in women. Arch Intern Med 2006;166:2462-8.
  • 82 Kang JH, Cook NR, Manson JE et al. VitaminE, vitamin C, beta carotene, and cognitive function among women withor at risk of cardiovascular disease: The Women s Antioxidant andCardiovascular Study. Circulation 2009;119:2772-80.
  • 83 Farina N, Isaac MGEKN, Clark AR, RustedJ, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitiveimpairment. Cochrane Database of Systematic Reviews 2012, Issue11. Art.No.:CD002854. DOI: 10.1002/14651858.CD002854.pub3.
  • 84 Meydani SN, Leka LS,Fine BC et al. Vitamin E and respiratory tract infections in elderlynursing home residents: a randomized controlled trial. JAMA 2004;292:828-36.
  • 85 GraatJM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineralsupplementation on acute respiratory tract infections in elderly persons:a randomized controlled trial. JAMA 2002;288:715-21.
  • 86 Agler AH, Kurth T, GazianoJM, et al. Randomised vitamin E supplementation and risk of chroniclung disease in the Women s Health Study. Thorax 2011;66:320-5.
  • 87 Klein AE, Thompson IM, Tangen CM et al.Vitamin E and the risk of prostate cancer. The selenium and vitaminE cancer prevention trial (Select). JAMA 2011;306:1549-56.
  • 88 Christen WG, Glynn RJ, Sesso HD, et al. Age-related cataract ina randomized trial of vitamins E and C in men. Arch ophtalmol 2010;128(11):1397-1405.
  • 89 Cockayne S,Adamson J, Lanham-New S. Vitamin K and the prevention of fractures:systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:1256-61.
  • 90 Marti-CarvajalAJ, Solà I. Vitamin K for upper gastrointestinal bleeding in patientswith acute or chronic liver disesases. Cochrane Database of SystematicReviews 2012, Issue 9. Art.No.:CD004792. DOI:10.1002/14651858.CD004792.pub4.
  • 91 Meerkerk GJ, Aarns T, DijkstraRH et al. NHG-standaard Problematisch alcoholgebruik (Tweede herziening). Huisarts Wet 2005;48;284-85. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M10_svk.htm.
  • 92 Raistrick D, Heather N, Godfrey C. Review of the effectiveness oftreatment for alcohol problems. National Treatment Agency for SubstanceMisuse. November 2006.http://www.nta.nhs.uk/uploads/nta_review_of_the_effectiveness_of_treatment_for_alcohol_problems_fullreport_2006_alcohol2.pdf.
  • 93 Charness ME, So YT. Wernicke sencephalopathy. UpToDate 2010. http://www.uptodateonline.com
  • 94 Scottish Intercollegiate GuidelinesNetwork. The management of harmful drinking and alcohol dependencein primary care. SIGN Publication n° 74, September 2003. http://www.sign.ac.uk/pdf/sign74.pdf.
  • 95 PRODIGY. Alcohol – problem drinking. PRODIGY 2007. http://prodigy.clarity.co.uk/alcohol_problem_drinking.
  • 96 Charness ME. Overview of the chronic neurologiccomplications of alcohol. UpToDate 2010. http://www.uptodateonline.com.
  • 97 Ang CD, Alviar MJ, Dans AL et al. VitaminB for treating peripheral neuropathy. Cochrane Database of SystematicReviews 2008, Issue 3. Art. No.: CD004573. DOI: 10.1002/14651858.CD004573.pub3.
  • 98 Gezondheidsraad.Voedingsnormen: calcium, vitamine D, thiamine, riboflavine, niacine,pantotheenzuur en biotine. Den Haag: Gezondheidsraad, 2000; publicatienr 2000/12. http://www.gezondheidsraad.nl/sites/default/files/00@12Nr2.pdf.
  • 99 Pazirandeh S, Lo CW, Burns D. Overviewof water-soluble vitamins. UpToDate 2009. http://www.uptodateonline.com.
  • 100 Gezondheidsraad. Voedingsnormen: vitamine B6, foliumzuur en vitamineB12. Den Haag: Gezondheidsraad, 2003; publicatie nr 2003/04. http://www.gezondheidsraad.nl/sites/default/files/03@04nr.pdf.
  • 101 Malouf R, Grimley Evans J. Vitamin B6 for cognition. CochraneDatabase of Systematic Reviews 2003, Issue 4. Art. No.:CD004393.DOI: 10.1002/14651858.CD004393.
  • 102 Martí-Carvajal AJ, Solà I, Lathyris D,Salanti G. Homocysteine lowering interventions for preventing cardiovascularevents. Cochrane Database of Systematic Reviews 2009, Issue4. Art. No.: CD006612. DOI: 10.1002/14651858.CD006612.pub2.
  • 103 Heinz J, Kropf S, Domröse U et al. B vitaminsand the risk of total mortality and cardiovascular disease in end-stagerenal disease. Circulation 2010;121:1432-8.
  • 104 Ebbing M, Bleie O, UelandPM et al. Mortality and cardiovascular events in patients treatedwith homocysteine-lowering B vitamins after coronary angiography. JAMA 2008;300:795-804.
  • 105 Zhang SM, Cook NR, Albert CM et al. Effect of combined folic acid,vitamin B6, and vitamin B12 on cancer risk in women: a randomizedtrial. JAMA 2008;300:2012-21.
  • 106 Christen WG, Glynn RJ, Chew EY et al. Folic acid, pyridoxine, andcyanocobalamin combination treatment and age-related macular degenerationin women: the Women s Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 2009;169:335-41.
  • 107 Katan M. Hoeveel vitamine B6 is toxisch? NedTijdschr Geneeskd 2005;149:2545.
  • 108 Gezondheidsraad. Voedingsnormen: Naar een optimaalgebruik van foliumzuur. Den Haag: Gezondheidsraad, 2008; publicatienr 2008/02. http://www.gezondheidsraad.nl/sites/default/files/200802N.pdf.
  • 109 PRODIGY.Dementia. PRODIGY 2010. http://prodigy.clarity.co.uk/dementia.
  • 110 Scottish Intercollegiate GuidelinesNetwork. Management of patients with dementia. SIGN Publication86, February 2006. http://www.sign.ac.uk/pdf/sign86.pdf.
  • 111 British Geriatrics Society. Guidelines for theprevention, diagnosis and management of delirium in older people inhospital. Published January 2006. http://www.bgs.org.uk
  • 112 Malouf R, Grimley Evans J. Folicacid with or without vitamin B12 for the prevention and treatmentof healthy elderly and demented people. Cochrane Database of SystematicReviews 2008, Issue 4. Art. No.: CD004514. DOI:10.1002/14651858.CD004514.pub2.
  • 113 Zhou YH, Tang JY, Wu MJ et al.Effect of folic acid supplementation on cardiovascular outcomes: asystematic review and meta-analysis. PLoS ONE 2011;6(9):e25142.
  • 114 Armitage JM, Bowman L, Clarke RJ et al.Effects of homocysteine-lowering with folic acid plus vitamin B12vs placebo on mortality and major morbidity in myocardial infarctionsurvivors. JAMA 2010;303:2486-94.
  • 115 Cole BF, Baron JA, Sandler RS et al. Folicacid for the prevention of colorectal adenomas: a randomized clinicaltrial. JAMA 2007;297:2351-9.
  • 116 Logan RF, Grainge MJ, Shepherd VC et al.Aspirin and folic acid for the prevention of recurrent colorectaladenomas. Gastroenterology 2008;134:29-38.
  • 117 Wu K, Platz EA, Willett WC et al. A randomizedtrial on folic acid supplementation and risk of recurrent colorectaladenoma. Am J Clin Nutr 2009;90:1623-31.
  • 118 Wien TN, Pike E, Wilsloff T et al. Cancerrisk with folic acid supplements: a systematic review and meta-analysis. BMJ Open 2012;2:e000653.
  • 119 Van Vlierberghe H,Bogaert M. Vitaminen en mineralen: wetgeving en toxiciteit. Tijdschrvoor Geneeskd 2003;58:1455-9.
  • 120 Carmel R. Cobalamin, thestomach and aging. Am J Clin Nutr 1997;66:750-9.
  • 121 Dali-YoucefN, Andrès E. An update on cobalamin deficiency in adults. QJM 2009;102:17-28.
  • 122 Joosten E,Fabri R. Is er plaats voor perorale therapie bij vitamine-B12-tekort? Tijdschr voor Geneeskd 2000;56:451-6.
  • 123 Alaball V, Butter CC. Editorial. Reducedserum vitamin B-12 in patients taking metformin. BMJ 2010;340:1147-8.
  • 124 De Jager J, Kooy A, LehertP, et al. Long term treatment with metformin in patients with type2 diabetes and risk of vitamin B-12 deficiency: randomized placebocontrolled trial. BMJ 2010;340:c2181.
  • 125 Snow CF. Laboratorydiagnosis of vitamin B12 and folate deficiency. Arch Intern Med 1999;159:1289-98.
  • 126 WiersingaWJ, De Rooij SEJA, Huijmans JGM et al. De diagnostiek van vitamine-B12-deficiëntieherzien. Ned Tijdschr Geneeskd 2005;149:2789-94.
  • 127 Titeca K, Van Heeringen C. Een delirium ten gevolge van een vitamine-B12-deficiëntie. Tijdschr voor Geneeskd 2001;57:379-81.
  • 128 MaloufR, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Databaseof Systematic Reviews 2003, Issue 3. Art. No.:CD004394. DOI: 10.1002/14651858.CD004394.
  • 129 Ebbing M, Bønaa KH, Nygård O et al. Cancerincidence and mortality after treatment with folic acid and vitaminB12. JAMA 2009;302:2119-26.
  • 130 Duyvendak M, VeldhuisGJ. Vitamine B12-suppletie liever oraal dan parenteraal. Ned TijdschrGeneeskd 2009;153:2107-11.
  • 131 Vidal-AlaballJ, Butler C, Cannings-John R et al. Oral vitamin B12 versus intramuscularvitamin B12 for vitamin B12 deficiency. Cochrane Database of SystematicReviews 2005, Issue 3. Art. No.: CD004655. DOI: 10.1002/14651858.CD004655.pub2.
  • 132 Anonymous.Oral or intramuscular vitamin B12. Drug Ther Bull 2009;47:19-21.
  • 133 Hemilä H, Chalker E, DouglasB. Vitamin C for preventing and treating the common cold. CochraneDatabase of Systematic Reviews 2007, Issue 3. Art. No.: CD000980.DOI: 10.1002/14651858.CD000980.pub3.
  • 134 Hemilä H, Louhiala P.Vitamin C for preventing and treating pneumonia. Cochrane Databaseof Systematic Reviews 2007, Issue 1. Art. No.: CD005532. DOI:10.1002/14651858.CD005532.pub2.
  • 135 El-Kadiki A, Sutton A. Role of multivitamins and mineral supplementsin preventing infections in elderly people: systematic review andmeta-analysis of randomized controlled trials. BMJ 2005;330:871.
  • 136 Avenell A, Campbell MK, Cook JAet al. Effect of multivitamin and multimineral supplements on morbidityfrom infections in older people (MAVIS trial): pragmatic, randomized,double blind, placebo controlled trial. BMJ 2005;324-9.
  • 137 Neuhouser ML, Wassertheil-SmollerS, Thomson C et al. Multivitamin use and risk of cancer and cardiovasculardisease in the Women’s Health Initiative Cohorts. Arch Intern Med 2009;169:294-304.
  • 138 ParkSY, Murphy SP, Wilkens LR, et al. Multivitamin Use and the Risk ofMortality and Cancer Incidence. The Multiethnic Cohort Study. Am.J. Epidemiol 2011;173:906-14.
  • 139 Stratton J, Godwin M. The effect of supplemental vitamins and mineralson the development of prostate cancer: a systematic review and meta-analysis. Family Practice 2011;8(3):243-52.
  • 140 Chang YJ, Myung S, Chung ST et al. Effects of vitamin treatmentor supplements with purported antioxidant properties on skin cancerprevention: a meta-analysis of randomized controlled trials. Dermatology 2011;223:36-44.
  • 141 Mursu J, Robien K, Harnack LJ et al. Dietarysupplements and mortality rate in older women. The Iowa Women’s Healthstudy. Arch Intern Med 2011;171:1625-33.
  • 142 Sesso HD,Christen WG, Bubes V, et al. Multivitamins in the prevention of cardiovasculardisease in men. The Physicians’ Health Study II randomized controlledtrial. JAMA 2012;308:1751-60.
  • 143 Myung SK. Efficacyof vitamin and antioxidant supplements in prevention of cardiovasculardisease: systematic review and meta-analysis of randomised controlledtrials. BMJ 2013;346:f10.
  • 144 Clarke R, Halsey J, Lewington S, et al, Vitamin Treatment Trialists Collaboration. Effects of lowering homocysteine levels with B vitaminson cardiovascular disease, cancer, and cause-specific mortality: Meta-analysisof 8 randomized trials involving 37 485 individuals. Arch InternMed 2010;170:1622-31.
  • 145 Lee M, Hong KS, Chang SC, et al. Efficacyof homocysteine-lowering therapy with folic Acid in stroke prevention:a meta-analysis. Stroke 2010;41:1205-12.
  • 146 House AA, Eliasziw M, Cattran DC, et al.Effect of B-vitamin therapy on progression of diabetic nephropathy:a randomized controlled trial. JAMA 2010;303:1603-9.
  • 147 Galan P, Kesse-Guyot E, Czernichow S, etal. Effects of B vitamins and omega3 fatty acids on cardiovasculardiseases: a randomized placebo controlled trial. BMJ 2010;341:c6273.
  • 148 Figueiredo JC, Grau MV, Haile RW et al.Folic acid and risk of prostate cancer: results from a randomizedclinical trial. J Natl Cancer Inst 2009;101:432-5.
  • 149 VollsetAE, Clarke R, Lewington S, et al. Effects of folic acid supplementationon overall and site-specific cancer incidence during the randomisedtrials: meta-analyses of data on 50 000 individuals. Lancet 2013;381:1029-36.
  • 150 Andreeva VA, Touvier M, Kesse-Guyot E etal. B vitamin and/or omega-3- fatty acid supplementation and cancer(SU.FOL.OM3). Arch Intern Med 2012;172(7):540-7.
  • 151 Hackam DG. Review:antioxidant supplements for primary and secondary prevention do notdecrease mortality. ACP J Club 2007 ;147:4. Analyse de: BjelakovicG, Nikolova D, Gluud LL et al. Mortality in randomized trials of antioxidantsupplements for primary and secondary prevention: systematic reviewand meta-analysis. JAMA 2007;297:842-57.
  • 152 PRODIGY. Age relatedmacular degeneration. PRODIGY 2010. http://prodigy.clarity.co.uk/macular_degeneration_age_related.
  • 153 Canadian Agency for Drugs and Technologiesin Health. Vitalux for the prevention and treatment of age-relatedmacular degeneration: clinical effectiveness. CADTH Rapid Response12 January 2011. http://www.cadth.ca/media/pdf//htis/jan-2011/K0301_Vitalux_AMD.pdf.
  • 154 Evans JR, LawrensonJG. Antioxidant vitamin and mineral supplements for preventing age-relatedmacular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD000253. DOI: 10.1002/14651858.CD000253.pub3.
  • 155 Christen WG, Glynn RJ, Sesso HD et al. Vitamins E and C and medicalrecord-confirmed age-related macular degeneration in a randomizedtrial of male physicians. Ophtalmology 2012;119:1642-9.
  • 156 Laekeman G, Chevalier P. Dégénérescence maculaire chez la femme:traitement antioxydant efficace? Minerva 2009;8:120-1. http://www.minerva-ebm.be/fr/article.asp?id=1786. Analyse de Christen WG, Glynn RJ, Chew EY et al. Vitamin E andage-related cataract in a randomized trial of women. Ophthalmology 2008;115:822-9. .
  • 157 Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowingthe progression of age-related macular degeneration. Cochrane Databaseof Systematic Reviews 2012, Issue 11. Art;No.:CD10015. DOI:10.1002/14651858.CD010015.pub2.
  • 158 Anonymous.Vitamins for cataract prevention. The Medical Letter 2008;50:46-7.
  • 159 Christen WG, Glynn RJ, Chew EY etal. Vitamin E and age-related cataract in a randomized trial of women. Ophthalmology 2008;115:822-9.
  • 160 Mathew MC, Ervin AM, TaoJ, Davis RM. Antioxidant vitamin supplementation for preventing andslowing the progression of age-related cataract. Cochrane Databaseof Systematic Reviews 2012, Issue 6. Art. No.: CD004567. DOI:10.1002/14651858.CD004567.pub2.
  • 161 Huysman F, Mathieu C. Behandeling van pijnlijkediabetische neuropathie: overzicht. Tijdschr voor Geneeskd 2009;7:275-81.
  • 162 GrodsteinF, Kang JH, Glynn RJ et al. A randomized trial of beta carotene supplementationand cognitive function in men: the Physicians Health Study II. Arch Intern Med 2007;167:2184-90.
  • 163 Centre Belge d’Information Pharmacothérapeutique. Traitement médicamenteuxde la démence. Fiche de Transparance. Juillet 2008 (avec misesà jour annuelles jusqu’à septembre 2010). http://www.cbip.be/pdf/tft/TF_Dem.pdf.
  • 164 Balk E, Raman G, Tatsioni A et al. Vitamin B6,B12 and folic acid supplementation and cognitive function. Arch InternMed 2007;167:21-30.
  • 165 Aisen PS,Schneider LS, Sano M et al. High-dose B vitamin supplementation andcognitive decline in Alzheimer disease. JAMA 2008;300:1774-83.
  • 166 Laekeman G. Vitamine B6, B12 ouacide folique: efficace sur les capacités cognitives. Minerva 2007;6:124-5.http://www.minerva-ebm.be/fr/article.asp?id=1337 Analyse de Balk E, Raman G, Tatsioni A et al. Vitamin B6, B12 andfolic acid supplementation and cognitive function. Arch InternMed 2007;167:21-30.
  • 167 Ford AH, Flicker L, Alfonso H, et al. Vitamins B(12), B(6), and folicacid for cognition in older men. Neurology 2010;75:1540-7.
  • 168 Sato Y, Honda Y, Iwamoto J et al. Effect of folateand mecobalamin on hip fractures in patients with stroke. JAMA 2005;293:1082-88.
  • 169 Sawka, AM,Ray, JG, Yi, Q, et al. Randomized clinical trial of homocysteine levellowering therapy and fractures. Arch Intern Med 2007;167:2136.
  • 170 van der SijsIH, Ho-Dac-Pannekeet MM. The treatment of hypomagnesemia. Ned TijdschrGeneeskd 2002;146:934-8.
  • 171 Young G. Leg cramps. BMJ Clinical Evidence2009;03:1113.Search Date September 2008http://www.clinicalevidence.bmj.com. .
  • 172 Semla T, Beizer J, Higbee M. Geriatric dosageHandbook. 8th Edition. Lexi-Comp Inc. 2004.
  • 173 Commissie Farmaceutische Hulp van het College voor zorgverzekeringen.Anemie door ijzergebrek, ijzerpreparaten. Farmacotherapeutisch Kompas2011. http://www.fk.cvz.nl.
  • 174 Van Wijk MAM, Mel M, Muller PA et al. NHG-StandaardAnemie. Huisarts Wet 2003;46(1):21-9. Rectificatie algoritme Huisarts Wet 2003;46(3):147. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M76_svk.htm.
  • 175 PRODIGY. Anaemia - Iron deficiency. PRODIGY 2008. http://prodigy.clarity.co.uk/anaemia_iron_deficiency.
  • 176 van der Linden MW. Ijzerpreparatenbij ijzergebreksanemie. GeBu 2009;43:13-8. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/IJzerpreparaten-bij-ijzergebreksanemie.htm.
  • 177 Rimon E, Kagansky N, Kagansky M et al. Are we giving too much iron?Low-dose iron therapy is effective in octogenarians. Am J Med 2005;118:1142-7.
  • 178 Ioannou G,Debley C. Low dose iron supplementation was effective in older patientswith iron deficincy anaemia. Evid Based Med 2006;11:89. Discussionof: Rimon E, Kagansky N, Kaansky M et al. Are we giving too much iron?Low-dose iron therapy is effective in octogenarians. Am J Med 2005;118:1142-7.
  • 179 Joosten E. Diagnostieken therapie van niet-oncologische anemie bij ouderen. Tijdschrvoor Geneeskd 2010;66:611-7.
  • 180 Rédaction Prescrire. Difficultésà avaler les médicaments: gare au sulfate de fer. Rev Prescr 2011;31:833. http://www.prescrire.org.
  • 181 Wilkinson EAJ, Hawke CC. Oralzinc for arterial and venous leg ulcers. Cochrane Database of SystematicReviews 1998, Issue 4. Art. No.: CD001273. DOI: 10.1002/14651858.CD001273.
  • 182 Science M, Johnstone J, Roth DE et al. Zinc for the treatment ofthe common cold: a systematic review and meta-analysis of randomizedcontrolled trials. CMAJ 2012;184:E551-61.
  • 183 Arrol B. Common cold. BMJ Clin Evid 2011;03:1510. Search DateJanuary 2010. http://clinicalevidence.bmj.com.
  • 184 Singh M, Das RR. Zinc fotthe common cold. Cochrane Database Syst Rev 2011:issue2CD0012364.DOI10.1002/14651858.CD001364.pub3.
  • 185 Klein EA, ThompsonIM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: theSelenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-56.
  • 186 Rees K, Hartley L, Day C, Flowers N, ClarkeA, Stranges S. Selenium supplementation for the primary preventionof cardiovascular disease. Cochrane Database of Systematic Reviews 2013,Issue1. Art.No.:CD009671.
  • 187 StrangesS, Marshall JR, Natarajan R et al. Effects of long-term selenium supplementationon the incidence of type 2 diabetes. Ann Intern Med 2007;147:217-23.risquenon statistiquement significativement augmenté dans la méta-analyseprécitée. Cette méta-analyse identifie par contre une augmentationde risque significative d’alopécie et de dermatite avec le sélénium

Dermatologie:

  • 1 Mulder WM, Meinardi MM, BruynzeelDP. Huidreacties door geneesmiddelen. Ned Tijdschr Geneeskd 2004;148:415-20.
  • 2 Gielen K, Goossens A. Contactallergische reactiesbij medisch personeel door geneesmiddelen. Tijdschr voor Geneeskd 2004;60:1776-84.
  • 3 HodgkinsonB, Nay R, Wilson J. A systematic review of topical skin care in agedcare facilities. J Clin Nurs 2007;16,129-36.
  • 4 Commission Belge de Pharmacopée. FormulaireThérapeutique Magistral. Edition 2010. Agence Fédérale des Médicamentset des Produits de Santé. http://www.fagg-afmps.be/fr/binaries/FTM_Pharmaciens_Edition_2010_tcm291-121380.pdf.
  • 5 National Institute for Health and Clinical Excellence. Frequencyof application of topical corticosteroids for atopic eczema. NICE Technology Appraisal 81, August 2004. http://guidance.nice.org.uk/TA81/Guidance/pdf/English.
  • 6 PRODIGY. Dermatitis – contact. PRODIGY 2005. http://prodigy.clarity.co.uk/dermatitis_contact.
  • 7 WilliamsH, Bigby M, Diepgen T et al. Evidence Based Dermatology. BMJBooks. April 2003.
  • 8 NationalPrescribing Centre. Atopic eczema in primary care. MeReC Bulletin 2004;14:1-4. http://www.npc.nhs.uk/merec/therap/skin/resources/merec_bulletin_vol14_no1.pdf.
  • 9 Schmitt J, ApfelbacherCJ, Flohr C. Eczema. BMJ Clinical Evidence 2011;05:1716. SearchDate May 2009. http://clinicalevidence.bmj.com.
  • 10 Anonymous. Bath emollients for atopic eczema:why use them? Drug Ther Bull 2007;45:73.
  • 11 Cork MJ, Danby S. Skin barrier breakdown:a renaissance in emollient therapy. Br J Nurs 2009;18:872,874, 876-7.
  • 12 CleveringaJP, Dirven-Meijer PC, Hartvelt-Faber G et al. NHG-Standaard Constitutioneeleczeem (Eerste herziening). Huisarts Wet 2006;49:458-65. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M37_svk.htm.
  • 13 Saary J, Qureshi R, Palda V et al. A systematic review of contactdermatitis treatment and prevention. J Am Acad Dermatol 2005;53:845-55.
  • 14 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Dermatocorticosteroïden.Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 15 Anonymous. Topical steroidsfor atopic dermatitis in primary care. Drug Ther Bull 2003;41:5-8.
  • 16 Green C, Colquitt JL, Kirby J et al. Clinical and cost-effectivenessof once-daily versus more frequent use of same potency topical corticosteroidsfor atopic eczema: a systematic review and economic evaluation. Health Technology Assessment 2004;8(47):1-134. http://www.hta.ac.uk/1372.
  • 17 WilliamsHC. Established corticosteroid creams should be applied only nce dailyin patients with atopic eczema. BMJ 2007;334:1272.
  • 18 Rédaction Prescrire. Tacrolimus dermique: tropd’inconnues pour utiliser cet immunosuppresseur par voie cutanée. Rev Prescrire 2003;23:805-9.
  • 19 AshcroftD, Dimmock P, Garside R et al. Efficacy and tolerability of topicalpimecrolimus and tacrolimus in the treatment of atopic dermatitis:meta-analysis of randomised controlled trials. BMJ 2005;330:516-22.
  • 20 Garside R, SteinK, Castelnuovo E et al. The effectiveness and cost-effectiveness ofpimecrolimus and tacrolimus for topic eczema: a systematic reviewand economic evaluation. Health Technology Assessment 2005;9(29)1-246. http://www.hta.ac.uk/1379.
  • 21 Rédaction Prescrire. Pimécrolimusou tacrolimus dermique et cancer. Rev Prescrire 2005;25:592. http://www.prescrire.org
  • 22 Rédaction Prescrire. Tacrolimusdermique: cancer (suite). Rev Prescr 2012;32:345. http://www.prescrire.org.
  • 23 EuropeanMedicines Agency. Questions and answers on Protopic/Protopy and Elidel. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Elidel_31/WC500012303.pdf.
  • 24 Anonymous.Pimecrolimus. Aust Prescr 2003;26:149-50.
  • 25 National Institute for Health andClinical Excellence. Tacrolimus and pimecrolimus for atopic eczema. NICE Technology Appraisal 82, August 2004. http://guidance.nice.org.uk/TA82.
  • 26 Naldi L. Seborrhoeic dermatitis. BMJ Clinical Evidence 2010;12:1713.Search date April 2010. http://clinicalevidence.bmj.com.
  • 27 Anonymous, Idées Forces, Dermatite séborrhéique:traitement Rev Prescrirefévrier 2013.
  • 28 Lareb (NederlandsBijwerkingen Centrum). Seleniumsulfide en huidirritatie. GeBu 2009;43:81. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Seleniumsulfide-Selsun-en-huidirritatie.htm.
  • 29 Van Zuuren EJ, Graber MA, Hollis S et al. Interventions for rosacea. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.:CD003262. DOI:10.1002/14651858.CD003262.pub3.
  • 30 Van Zuuren EJ, Gupta AK, Gover MD, Graber M, HollisS. Systematic review of rosacea treatments. J Am Acad Dermatol2007; 56:107-15.
  • 31 Korting HC, Schöllmann C. Current topical andsystemical approaches to treatment of rosacea. J Eur Acad DermatolVenereol 2009;23:876-82.
  • 32 Anonymous. De behandelingvan rosacea. Geneesmiddelenbulletin 1998;32:101-5. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/De-behandeling-van-rosacea.htm.
  • 33 Finnish Medical Society Duodecim. Psoriasis. In: EBM Guidelines.Evidence-Based Medicine Helsinki Finland.
  • 34 Naldi L, Rzany B.Psoriasis (chronic plaque). BMJ Clinical Evidence 2009;01:1706.Search Date August 2007. http://clinicalevidence.bmj.com.
  • 35 Centre Belge d’Information Pharmacothérapeutique. Analogues dela vitamine D en cas de psoriasis. Folia Pharmacotherapeutica 2003;30:7-8. http://www.cbip.be/PDF/Folia/2003/P30F01D.pdf.
  • 36 Van Hecke E. Calcipotriol voor chronische plaque psoriasis. Minerva (Huisarts Nu) 2002;32:378-80. http://www.minerva-ebm.be/nl/article.asp?id=575.
  • 37 Lantinga H, Ek JW, NijmanFC et al. NHG-Standaard Psoriasis (tweede herziening). http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M39_svk.htm.
  • 38 Bruner CR, Feldman SR, Ventrapragada M et al.A systematic review of adverse effects associated with topical treatmentsfor psoriasis. Dermatol Online J 2003;9:2.
  • 39 Afifi T, de Gannes G, Huang C et al. Topical therapiesfor psoriasis: evidence-based review. Can Fam Physician 2005;51:519-25.
  • 40 National HealthService Scotland. Re-submission: Calcipotriol and betamethasone dipropionateointment. Scottisch Medicines Consortium Advice, 12 December 2005. http://www.scottishmedicines.org.uk/files/Calcipotriol_betamethasone__Dovobet_-Resubmission_09-02.pdf.
  • 41 Mason AR, Mason J, CorkM, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2013, Issue 3. Art. No.:CD005028. DOI: 10.1002/14651858.CD005028.pub3.
  • 42 Rédaction Prescrire. Cancers cutanés après puvathérapie. Rev Prescrire 2005;261:353.
  • 43 Rédaction Prescrire. Antibiotiques locaux (suite):retraits et restrictions bienvenus dans les infections cutanées. Rev Prescrire 2009;29(305):181.
  • 44 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Middelen bij wondbehandelingen desinfectie van de huid. Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 45 George A, Rubin G. Asystematic review and meta-analysis of treatments for impétigo. Br J Gen Pract 2003;53:480-7.
  • 46 Koning S, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, ButlerC, van der Wouden JC. Interventions for impétigo. Cochrane Databaseof Systematic Reviews 2003, Issue 2. Art. No.: CD003261. DOI:10.1002/14651858.CD003261.pub2.
  • 47 Koning S, van der Sande R, Verhagen AP,van Suijlekom-Smit LWA, Morris AD, Butler CC, Berger M, van der WoudenJC. Interventions for impetigo. Cochrane Database of SystematicReviews. 2012, Issue 1. Art. No.: CD003261. DOI: 10.1002/14651858.CD003261.pub3.
  • 48 Health Protection Agency. Management of infectionguidance for primary care for consultation & local adaptation. Health Protection Agency. Latest review March-July 2010. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1279888711402.
  • 49 Ammerlaan et al. , Eradication of methicillin-resistantStaphylococcus aureus carriage: a systematic review, Clin infect.Dis. 2009: 922-30
  • 50 Gemmellet al., Guidelines for the prophylaxis and treatment of methicillin-resistantStaphylococcus aureus (MRSA) infections in the UK, J Antimicrob.Chemother. 2006: 589-608..
  • 51 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Bacteriële huidinfecties.Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 52 Belgian Antibiotic Policy CoordinationCommittee (BAPCOC). Guide belge des traitements anti-infectieux enpratique ambulatoire. Edition 2008. http://www.health.belgium.be/eportal/Myhealth/Care/Properuse/Antibiotics/index.htm.
  • 53 Boukes FS, Van der BurghJJ, Nijman FC et al. NHG-Standaard Bacteriële Huidinfecties. HuisartsWet 1998;41:427-37. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M68_svk.htm.
  • 54 Laube S, Farrell AM. Bacterialskin infections in the elderly: diagnosis and treatment. DrugsAging 2002;19:331-42.
  • 55 Morris AD. Cellulitisand erysipelas. BMJ Clinical Evidence 2008;01:1708. SearchDate May 2007. . http://clinicalevidence.bmj.com.
  • 56 PRODIGY. Cellulitis. PRODIGY 2006. http://prodigy.clarity.co.uk/cellulitis_acute.
  • 57 Von den Driesch P. Candidiasis. Evidence Based Dermatology. BMJ Books. April 2003, p. 490-500.
  • 58 Centre Belge d’InformationPharmacothérapeutique. Répertoire Commenté des Médicaments 2011. www.cbip.be
  • 59 Van Puijenbroek EP, Duyvendak RJP, De Kock CAet al. NHG-Standaard Dermatomycosen, eerste herziening. HuisartsWet 2008;51(2):76-84. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M64_svk.htm.
  • 60 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Dermatomycosen. FarmacotherapeutischKompas 2011. http://www.fk.cvz.nl.
  • 61 Crawford F. Athlete’s foot. BMJ Clinical Evidence 2009;07:1712. Search Date July 2008. http://clinicalevidence.bmj.com.
  • 62 PRODIGY. Fungal (dermatophyte) skin infections. PRODIGY 2006. http://prodigy.clarity.co.uk/fungal_skin_infection_body_and_groin.
  • 63 Bell-Syer SEM, Khan SM, Torgerson DJ. Oraltreatments for fungal infections of the skin of the foot.CochraneDatabase of Systematic Reviews. 2012, Issue 10. Art. No.: CD003584.DOI: 10.1002/14651858.CD003584.pub2.
  • 64 PRODIGY. Fungal and candidalnail infection. PRODIGY 2006. http://prodigy.clarity.co.uk/fungal_nail_infection.
  • 65 RédactionPrescrire. Mycoses ungéales. Rev Prescrire 2008;28:205-11.maisson fort onéreuses, contrairement au miconazole
  • 66 Szepietowski JC, Reich A, Garlowska E, et al.Factors Influencing Coexistence of Toenail Onychomycosis With TineaPedis and Other Dermatomycosis: A Survey of 2761 Patients. ArchDermatol 2006;142:279-84.
  • 67 FerrariJ. Fungal nail infections. BMJ Clinical Evidence 2011;08:1715.Search Date March 2011. . http://clinicalevidence.bmj.com.
  • 68 Amabile CM, Spencer AP. Keepingyour patient with heart failure safe: a review of potentially dangerousmedications. Arch Intern Med 2004;164:709-20.
  • 69 Rédaction Prescrire. Syndrome de Lyell et terbinafine. Rev Prescr 2010;30:832.
  • 70 PRODIGY. Warts (including verrucas). PRODIGY 2007. http://prodigy.clarity.co.uk/warts_and_verrucae.
  • 71 Loo SK, Tang YM. Warts(non-genital). BMJ Clinical Evidence 2009;09:1710.Search DateJune 2008. http://clinicalevidence.bmj.com.
  • 72 Bruggink SC, Gussekloo J, Berger MY et al. Stikstoftherapie is deeffectiefste behandeling voor handwratten in de huisartsenpraktijk. Ned Tijdschr Geneeskd 2011;155:A3134.
  • 73 Bruggink SC,Assendelft WJJ, cryotherapy for plantar warts more costly but no moreeffective than salicylic acid self-treatment, Evid Based Med, 2012;17 (5): 156 comment on: Cockayne S et al., cryotherapy versus salicylicacid for the treatment of verrucae - a randomized controlled trial Health Technol Assess 2011; 15:1-170.
  • 74 Rédaction Prescrire. Varicelleou zona et anti-inflammatoires non stéroïdiens: complications cutanéesgraves. Rev Prescrire 2009;29:906-907.
  • 75 Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidalanti-inflammatory drug use and the risk of severe skin and soft tissuecomplications in patients with varicella or zoster disease. BrJ Clin Pharmacol 2008;65:203-209.
  • 76 Li Q, Chen N, Yang J et al. Antiviral treatment for preventing postherpeticneuralgia. Cochrane Database of Systematic Reviews 2009, Issue2. Art. No.: CD006866. DOI: 10.1002/14651858.CD006866.pub2.
  • 77 Centre Belge d’Information Pharmacothérapeutique. La prise en chargedu zona. Fiche de transparence Juin 2010. http://www.cbip.be/pdf/tft/TF_Zona_Lng.pdf.
  • 78 Oxman MN, Levin MJ et al. A vaccineto prevent Herpes Zoster and Postherpetic Neuralgia in older adults. N Engl J Med 2005;352:2271-84.
  • 79 Fekete T. A varicella-zoster virus vaccine reduced the burden ofillness of herpes zoster in older adults. Evid Based Med 2005;10:177.
  • 80 Chen N, Li Q, Zhang Y et al. Vaccination for preventing postherpeticneuralgia. Cochrane Database of Systematic Reviews 2011, Issue3. Art. No.:CD007795. DOI: 10.1002/14651858.CD007795.pub2.
  • 81 Redaction Prescrire. Vaccinzona. Peu efficace pour ceux qui en ont le plus besoin. Rev Prescr 2012;32:178. http://www.prescrire.org.
  • 82 Bilcke J, Marais C, Benson O et al. Rapportcoût-utilité de la vaccination contre la varicelle chez les enfants,et de la vaccination contre le zona chez les adultes en Belgique.Centre Fédéral d’Expertise des Soins et de Santé. KCE reports vol.151B, 2010. http://www.kce.fgov.be/sites/default/files/page_documents/kce_151b_vaccination_contre_varicelle_et_zona.pdf.
  • 83 LapeereH. Aanpak van schurft in rust- en verzorgingstehuizen. Tijdschrvoor Geneeskd 2007;63:235-7.
  • 84 Johnstone P, StrongM. Scabies. BMJ Clinical Evidence 2008;08:1707. Search DateOctober 2007. http://clinicalevidence.bmj.com.
  • 85 PRODIGY. Scabies. PRODIGY 2007. http://prodigy.clarity.co.uk/scabies.
  • 86 Anonymus, Idées Forces, Gale: traitement Rev Prescrire mars 2013.
  • 87 Redaction FormulaireMRS. Plaie chroniques chez la personne âgée: causes et prévention. Geneesmiddelenbrief 2007;14:33-42. http://www.farmaka.be/fr/formulRinfo/2007_09_formulrinfo.pdf.
  • 88 Fernandez R, Griffiths R. Water for wound cleansing. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.:CD003861. DOI: 10.1002/14651858.CD003861.pub2.
  • 89 Vanderwee K, Grypdonck M, DefloorT. Non-blanchable erythema as an indicator for the need for pressureulcer prevention: a randomized-controlled trial. J Clin Nurs 2007;16,325-35.
  • 90 Nixon J, Cranny G, Iglesias Cet al. Randomised, controlled trial of alternating pressure mattressescompared with alternating pressure overlays for the prevention ofpressure ulcers: PRESSURE (pressure relieving support surfaces) trial. BMJ 2006;332:1413-5.
  • 91 ReddyM. Pressure ulcers. BMJ Clinical Evidence 2011;05:1901. SearchDate June 2010. http://clinicalevidence.bmj.com.
  • 92 NationalInstitute for Health and Clinical Excellence, Royal College of Nursing.The management of pressure ulcers in primary and secondary care. Aclinical practice guideline. NICE Clinical Guideline 29, 2005. http://guidance.nice.org.uk/CG29.
  • 93 Chel VGM, Germs PH, Van der Wal J et al. NHG-Standaarddecubitus. Huisarts Wet 1999;42:165-72. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M70_svk.htm.
  • 94 Moore ZEH, Cowman S. Wound cleansing for pressure ulcers. CochraneDatabase of Systematic Reviews 2005, Issue 4. Art No.: CD004983.pub2.DOI:10.1002/14651858. CD04983.pub2.
  • 95 https://kce.fgov.be/sites/default/files
  • 96 Bergin SM, Wraight P. Silver basedwound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews 2006, Issue 1. Art.No.:CD005082.pub2.DOI: 10.1002/14651858.CD005082.pub2.
  • 97 Nelson EA, Jones J.Venous leg ulcers. BMJ Clinical Evidence 2008;09:1902. SearchDate September 2007. http://clinicalevidence.bmj.com.
  • 98 Van Hof N, Balak FSR, Apeldoorn L et al. NHG-Standaard Ulcus crurisvenosum. Huisarts Wet 2010;53:321-33. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M16_svk.htm.
  • 99 Nederlandse Vereniging voorDermatologie en Venerologie. Richtlijn Diagnostiek en behandelingvan het ulcus cruris venosum. NVDV, 2005. http://www.huidarts.info/documents/?v=2&id=75.
  • 100 Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healingvenous leg ulcers. Cochrane Database of Systematic Reviews 2006,Issue 3. Art. No.: CD001103. DOI: 10.1002/14651858.CD001103.pub2.
  • 101 Weiss EA, Oldham G, Lin M et al., wateris a safe and effective alternative to sterile normale saline forwound irrigation prior to suturing: a prospective, double-blind, randomised,controlled clinical trial, BMJ Open, 2013; january.
  • 102 NelsonEA, Bradley MD. Dressings and topical agents for arterial leg ulcers. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.:CD001836. DOI:10.1002/14651858.CD001836.pub2.
  • 103 Hunt D. Diabetes: foot ulcers and amputations. BMJ Clinical Evidence 2011;08:602. Search Date September 2010. http://clinicalevidence.bmj.com.
  • 104 JeffcoateWJ, Price PE, Phillips CJ et al. Randomised controlled trial of theuse of three dressing preparations in the management of chronic ulcerationof the foot in diabetes. Health Technol Assess 2009;13:1-86.
  • 105 DumvilleJC, Deshpande S, O’Meara S, Speak K. Foam dressings for healing diabeticfoot ulcers. Cochrane Database of Systematic Reviews 2011,Issue 9. Art. No. CD009111. DOI: 10.1002/14651858.CD00911.pub2.
  • 106 Dumville JC, O’Meara S, DeshpandeS, Speak K. Alginate dressings for healing diabetic foot ulcers. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.:CD009110. DOI: 10.1002/14651858.CD009110.pub2.
  • 107 Dumville JC, Deshpande S, O’Meara S, SpeakK. Hydrocolloid dressings for healing diabetic foot ulcers. CochraneDatabase of Systematic Reviews 2012, Issue 2. Art. No.: CD009099.DOI: 10.1002/14651858.CD009099.pub2.
  • 108 Dumville JC, O’Meara S, Deshpande S, SpeakK. Hydrogel dressings for healing diabetic foot ulcers. CochraneDatabase of Systematic Reviews 2011, Issue 9. Art. No.: CD009101.DOI: 10.1002/14651858.CD009101.pub2.
  • 109 Hailey D, Jacobs P, Perry DC e.a. Adjunctive Hyperbaric Oxygen Therapyfor Diabetic Foot Ulcer: An Economic Analysis Canadian Agency forDrugs and Technology in Health, Technology overview no 75, 2007. http://www.cadth.ca/en/publication/688.
  • 110 Vlayen J, Camberlin C, Ramaekers D. Traitementde plaies par pression négative: une évaluation rapide. Centre Fédérald’Expertise des Soins de Santé, KCE Reports vol. 61B, 2007. http://www.kce.fgov.be/sites/default/files/page_documents/d20071027331.pdf.http://www.kce.fgov.be/index_nl.aspx?SGREF=8948&CREF=9616
  • 111 Rédaction Prescrire. Brûlures cutanéessans gravité d’origine thermique. Rev Prescr 2011;31:116-23.
  • 112 Wasiak J, Cleland H. Burns (minor thermal). BMJClinical Evidence 2009;10:1903. Search Date October 2008. http://clinicalevidence.bmj.com.
  • 113 PRODIGY. Itch – widespread. PRODIGY 2010. http://prodigy.clarity.co.uk/itch_widespread.

Ophtalmologie:

  • 1 Rietveld RP, CleveringaJP et al. NHG-Standaard Het rode oog. Huisarts Wet 2006;49:78-91. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M57_svk.htm.
  • 2 Rietveld R, Ter Riet G etal. Met drie vragen naar de diagnose bacteriële infectieuze conjunctivitis;cohortonderzoek naar de waarde van combinaties van klachten en symptomen. Huisarts Wet 2005;48:53-8.
  • 3 Sheikh A, Hurwitz B. Topical antibioticsfor acute bacterial conjunctivitis. Cochrane Systematic review andmeta-analysis update. Br J Gen Practice 2005;55:962-4.
  • 4 PRODIGY. Conjunctivitis - Infective. PRODIGY 2007. http://prodigy.clarity.co.uk/conjunctivitis_infective.
  • 5 Anonymous. New topical drugsfor open-angle glaucoma. Drug Ther Bull 2003;41:12-6.
  • 6 Rose PW, Harnden A, et al. Chloramphenicol treatmentfor acute infective conjunctivitis in children in primary care: arandomised double-blind placebo-controlled trial. Lancet 2005;366:37-43.
  • 7 Rietveld R, ter Riet G et al. Thetreatment of acute infectious conjunctivitis with fusidic acid: arandomised controlled trial. Br J Gen Pract 2005;55:924-30.
  • 8 ChevalierP. Acide fusidique pour traiter la conjonctivite? Minerva 2006;5:142-4. http://www.minerva-ebm.be/fr/article.asp?id=1178.
  • 9 EplingJ. Bacterial conjunctivitis. BMJ Clinical Evidence 2010;03:704.Search Date July 2009. http://clinicalevidence.bmj.com.
  • 10 Everitt HA, Little PS et al. A randomized controlled trial of managementstrategies for acute infective conjunctivitis in general practice. BMJ 2006;333:321-6.
  • 11 Commissie Farmaceutische Hulp van het Collegevoor Zorgverzekeringen. Middelen bij ooginfecties. FarmacotherapeutischKompas 2011. http://www.fk.cvz.nl.
  • 12 Centre Belge d’Information Pharmacothérapeutique.Prise en charge du zona: traitement de l’herpès zoster ophtalmique. Fiche de transparence Juin 2010: p. 9. http://www.cbip.be/pdf/tft/TF_Zona_Lng.pdf.
  • 13 Anonymous. Herpes zoster undpostherpetische neuralgie. Arznei-telegramm 2003;34:13-4.
  • 14 Commissie Farmaceutische Hulp van het College voor Zorgverzekeringen.Middelen in allergische conjunctivitis. Farmacotherapeutisch Kompas 2011.http://www.fk.cvz.nl.
  • 15 RédactionPrescrire. Collyres à visée antiallergique. Rev Prescrire 2007;27:182.
  • 16 Owen CG, Shah A et al. Topical treatments forseasonal allergic conjunctivitis: systematic review and meta-analysisof efficacy and effectiveness. Br J Gen Pract 2004;54:451-6.
  • 17 PRODIGY. Conjunctivitis- Allergic. PRODIGY 2007. http://prodigy.clarity.co.uk/conjunctivitis_allergic.
  • 18 Rédaction Prescrire. Collyres anti-inflammatoire+ antibiotique. Aucun intérêt clinique après chirurgie de la cataracte. Rev Prescrire 2003;21:94-6.
  • 19 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Middelen bij droge ogen.Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 20 PRODIGY. Dry eye syndrome. PRODIGY 2008. http://prodigy.clarity.co.uk/dry_eye_syndrome.
  • 21 Centre Belge d’information Pharmacothérapeutique. Gels à base detimolol en cas de glaucome. Folia Pharmacotherapeutica 2004;31:44. http://www.cbip.be/PDF/Folia/2004/P31F05G.pdf.
  • 22 Shah R, Wormald R. Glaucoma. BMJ Clinical Evidence 2011;06:703. Search Date May 2010. http://clinicalevidence.bmj.com.
  • 23 Maier PC, Funk J, et al. Treatment of ocular hypertension and openangle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134-6.
  • 24 Chevalier P. Traitementde l’hypertension intra-oculaire et du glaucome. Minerva 2006;5:60-1. http://www.minerva-ebm.be/fr/article.asp?id=1107.
  • 25 Rédaction Prescrire. Glaucomeschroniques à angle ouvert. Idées-forces tirées de la revue Prescrirejusqu’au n° 269 (février 2006). http://www.prescrire.org.
  • 26 Agency for Healthcare Research and Quality. Effective Health CareProgram. Treatment for glaucoma: comparative effectiveness. AHRQComparative Effectiveness Review Number 60, 2012. http://www.effectivehealthcare.ahrq.gov/ehc/products/183/1023/CER60_GlaucomaTreatment_execsumm.pdf.
  • 27 Wiggins M, Uwaydat SH. Age-relatedmacular degeneration: options for earlier detection and improved treatment. J Fam Practice 2006;55:22-7.
  • 28 www.pxe.nl/amsler_grid.htm.
  • 29 Anonymous. Nutritional supplements for maculardegeneration. Drug Ther Bull 2006;44:9-11.
  • 30 Augood C, VingerlingJR et al. Prevalence of age-related maculopathy in older europeans.The European Eye Study (EUREYE). Arch Ophtalmol 2006;124:529-35.
  • 31 VanLeeuwen R, Boekhoorn S et al. Dietary intake of antioxidants and riskof age-related macular degeneration. JAMA 2005;24:3101-7.
  • 32 Evans JR. Primary prevention of age related maculardegeneration. BMJ 2007;335:729.
  • 33 Evans JR, Henshaw K. Antioxidant vitamin and mineralsupplements for preventing age-related macular degeneration. CochraneDatabase of Systematic Reviews 2008, Issue 1. Art. No.: CD000253.DOI: 10.1002/14651858.CD000253.pub2.
  • 34 Cugati S, Mitchell Pet al. Cataract surgery andthe 10-year incidence of age-related maculopathy: the Blue MountainsEye Study. Ophtalmology. 2006;113:2020-5.
  • 35 Evans JR. Antioxidantvitamin and mineral supplements for slowing the progression of age-relatedmacular degeneration. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub2.
  • 36 Rédaction Prescrire. Pegaptanib dans la dégénérescence maculaire:trop de risques pour trop peu de bénéfices. Rev Prescrire 2006;26:333.

Oto-rhino-laryngologie:

  • 1 DeGuzman DA, Bettcher CM, Harrison RV et al. Allergic rhinitis.University of Michigan Health System; October 2007. http://www.med.umich.edu/1info/fhp/practiceguides/allergic/allergic.pdf.
  • 2 Harvey R, Hannan SA, Badia L, Scadding G. Nasalsaline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.:CD006394. DOI: 10.1002/14651858.CD006394.pub2
  • 3 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Middelen bij allergischerhinitis. Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 4 Sheikh A, Panesar SS, Salvilla S. Hay fever inadolescents and adults. BMJ Clinical Evidence 2009;11:509.Search Date April 2008. http://clinicalevidence.bmj.com.
  • 5 Rédaction Prescrire. Bromure d ipratropium: nouvelleindication. Rev Prescrire 1987;7:114.
  • 6 PRODIGY. Allergic rhinitis. PRODIGY 2008. http://prodigy.clarity.co.uk/allergic_rhinitis.
  • 7 Grainer J, Drake-Lee A. Montelukast in allergicrhinitis: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:360-7.
  • 8 Radulovic S, Calderon MA, Wilson D, DurhamS. Sublingual immunotherapy for allergic rhinitis. Cochrane Databaseof Systematic Reviews 2010, Issue 12. Art. No.: CD 002893. DOI:10.1002/14651858.CD002893.pub2.
  • 9 Rédaction Prescrire. Grazax® lyophilisantsoraux: Commercialisation effective. Rev Prescr 2011;31:99.
  • 10 Sachs AP, Berger MY,Lucassen PL et al. NHG-Standaard Allergische en niet-allergische rhinitis,eerste herziening. Huisarts Wet 2006;49:254-65. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M48_svk.htm.
  • 11 Rédaction Formulaire MRS.Soins de bouche. Formul R/ info 2012;19(4):1-4. http://www.farmaka.be/fr/formulRinfo/2012_11_formulrinfo.pdf.
  • 12 Vissink A, Spiskervet F, Stegenga B. Geneesmiddelenbij aandoeningen van mond, gebit en kaak. GeBu 2001;35:119-26. http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Geneesmiddelen-bij-aandoeningen-van-mond-gebit-en-kaak.htm.
  • 13 Porter S, ScullyC. Aphthous ulcers (recurrent). BMJ Clinical Evidence 2007;06:1303.Search Date August 2006. http://clinicalevidence.bmj.com.
  • 14 Barrons RW. Treatment strategyfor recurrent oral aphtous ulcers. Am J Health Syst Pharm 2001;58:41-50.
  • 15 Rédaction Prescrire. Mucitesorales dues aux traitements anticancéreux. Hygiène buccodentaire etglaçons à sucer. Rev Prescrire 2007;27:286-8.
  • 16 Scully C, PorterS. Halitosis. BMJ Clinical Evidence 2008;07:1305. Search DateJuly 2008. http://clinicalevidence.bmj.com.
  • 17 Outhouse TL, Al-Alawi R, Fedorowicz Z, KeenanJV. Tongue scraping for treating halitosis. Cochrane Database ofSystematic Reviews 2006, Issue 2. Art. No.: CD005519. DOI:10.1002/14651858.CD005519.pub2.
  • 18 Commissie FarmaceutischeHulp van het College voor Zorgverzekeringen. Overige mond- en keelmiddelen.Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.
  • 19 Darby I. Drugsand gingival bleeding. Austr Prescr 2006;29:154-5.
  • 20 Rédaction Prescrire.Accroissements gingivaux d’origine médicamenteuse. Rev Prescr 2011;31:432-3. http://www.prescrire.org.
  • 21 Centre Belge d’InformationPharmacothérapeutique. Sécheresse de la bouche: étiologie et priseen charge. Folia Pharmacotherapeutica 2010;37:3-4. http://www.cbip.be/PDF/Folia/2010/P37F01C.pdf.
  • 22 Anonymous. Zur Erinnering – Geschmacksverlust durch terbinafin. Arznei-telegramm 2010;41:98.
  • 23 Browning G. Ear wax. BMJ Clinical Evidence 2008;01:504. Search Date June 2007. http://clinicalevidence.bmj.com.
  • 24 Roland PS, Eaton DA, Gross RD et al. Randomized,placebo-controlled evaluation of cerumenex and murine earwax removalproducts. Arch Otolaryngol Head Neck Surg 2004;130:1175-7.
  • 25 Eekhof J, Neven AK. Cerumen. Huisarts Wet 2009;52:251-3.
  • 26 Chevalier P. Traitement local de l’otite externe. Minerva 2004;3:101-2. http://www.minerva-ebm.be/fr/article.asp?id=826.
  • 27 Hajioff D, Mackeith S. Otitis externa. BMJClinical Evidence 2010;08:510. Search Date October 2007. http://clinicalevidence.bmj.com.
  • 28 Van Balen FA, SmitWM, Zuithoff NP, Verheij TJ. Clinical efficacy of three common treatmentsin acute otitis externa in primary care: a randomised controlled trial. BMJ 2003;327:1201-5.
  • 29 Rooijackers-Lemmens E, van Wijngaarden JJ, OpsteltenW et al. NHG Standaard Otitis Externa. http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M49_svk.htm.
  • 30 Commissie Farmaceutische Hulp van het Collegevoor Zorgverzekeringen. Middelen bij ooraandoeningen. Middelen bijoorinfecties. Farmacotherapeutisch Kompas 2011. http://www.fk.cvz.nl.

Trousse d’urgence: